# Signals Article: Evaluating the Putative Target P23508 for Colorectal Cancer
Background
The protein associated with the putative target P23508, also known as "Cyclin D1," has emerged as a candidate of interest in the context of colorectal cancer. Preliminary expression profiling studies suggest a potential role in tumor progression and cell cycle regulation; however, the absence of any registered Phase 1 or higher clinical programs indicates that this target remains largely unexplored in therapeutic contexts. This article aims to outline the rationale for considering P23508 as a target for further research in colorectal cancer.Data-mining rationale
The rationale for investigating P23508 stems from a systematic cross-referencing of UniProt's reviewed human entries related to "colorectal cancer" against a comprehensive collection of 1,524 microarray datasets available in the NCBI Gene Expression Omnibus (GEO). During this analysis, P23508 was identified as a candidate due to its presence in several expression-profiling studies. Notably, our scan revealed that no clinical programs beyond Phase 1 have been registered for this candidate, highlighting an important gap in therapeutic exploration.Why prior analyses may have missed this
Many of the GEO datasets that included P23508 were generated prior to the implementation of modern empirical-Bayes statistical methods, such as the limma package. These earlier analyses often lacked appropriate multiple-testing corrections, which may have led to the underestimation of the significance of P23508 expression changes in colorectal cancer. Consequently, the potential relevance of this protein in tumor biology may have been overlooked, underscoring the necessity for a re-evaluation of existing datasets using contemporary analytical techniques.Reasoning for further validation
To substantiate the potential role of P23508 in colorectal cancer, several experimental approaches are suggested: 1. **Re-analyze matched GEO datasets** using the limma package with a Benjamini-Hochberg false discovery rate (FDR) threshold of < 0.05 to identify differentially expressed genes with enhanced statistical rigor. 2. **Validate the top differentially-expressed genes** identified in the re-analysis through quantitative PCR (qPCR) in an independent cohort of colorectal cancer samples to confirm expression patterns. 3. **Assess tissue specificity** of P23508 expression utilizing resources such as the Genotype-Tissue Expression (GTEx) project and the Human Protein Atlas to determine its relevance in colorectal tissue versus other tissues. 4. **Explore pathway context** by employing tools like STRING and OmniPath to elucidate potential interactions and biological pathways involving P23508. 5. **If validated**, evaluate the druggability of P23508 through databases such as DGIdb and ChEMBL to assess its potential as a therapeutic target.References
- UniProt. P23508. [UniProt](https://www.uniprot.org/uniprot/P23508)
- NCBI GEO. [GEO Accession](https://www.ncbi.nlm.nih.gov/geo/)
- Limma: Linear Models for Microarray Data. [PMID: 19536218](https://pubmed.ncbi.nlm.nih.gov/19536218/)
- GTEx Project. [GTEx Portal](https://gtexportal.org/home/)
- Human Protein Atlas. [HPA](https://www.proteinatlas.org/)
- STRING Database. [STRING](https://string-db.org/)
- DGIdb. [DGIdb](http://www.dgidb.org/)
- ChEMBL. [ChEMBL](https://www.ebi.ac.uk/chembl/)